Difference between revisions of "Tremelimumab (Imjudo)"
Warner-admin (talk | contribs) m (Text replacement - "Category:Immunotherapy" to "Category:Immunotherapeutic") |
m (→Also known as) |
||
| Line 8: | Line 8: | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' CP-675,206 | *'''Code name:''' CP-675,206 | ||
| + | *'''Generic name:''' ticilimumab | ||
==References== | ==References== | ||
Revision as of 20:14, 15 December 2019
General information
Class/mechanism: Anti-CTLA-4 antibody. CTLA-4 is a negative regulator of T-cell activation and ipilimumab interferes with the ability of CTLA-4 to interact with its ligands CD80/CD86. CTLA-4 blockade results in T-cell activation and proliferation, and it is suspected that its anti-neoplastic activity may be due to T-cell mediated anti-tumor immune responses.[1][2]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Also known as
- Code name: CP-675,206
- Generic name: ticilimumab